Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
about
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesiumItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.H+/K+-ATPase inhibitors: a patent review.Mechanism of acid hypersecretion post curative gastrinoma resectionZollinger-Ellison syndrome: classical considerations and current controversies.Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advancesProgress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialVIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasSerum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?HypergastrinemiaDiagnosis of Zollinger-Ellison syndrome: increasingly difficult.Pharmacotherapy of Zollinger-Ellison syndrome.Gastrin - active participant or bystander in gastric carcinogenesis?Gastric acid hypersecretory states: recent insights and advances.Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells.Pharmaceutical principles of acid inhibitors: unmet needs.Zollinger-Ellison syndrome: recent advances and controversies.Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers.Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.Cobalamin deficiency in elderly patients: a personal view.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionImportance of gastrin in the pathogenesis and treatment of gastric tumors.Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors.Short-term and long-term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open-label, pilot, randomized trial.Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study.Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial
P2860
Q24603675-CE4270FD-B2ED-4318-BA15-0335DBE18D3FQ30487910-2E5B2089-1B1A-4AD7-AB72-E40086CB2946Q34140914-A6A1077A-BDB6-48F1-91DE-FBFDEB4A814AQ34157385-380A716C-24D1-4C14-8A62-E5A4FDB2B36EQ34315036-051AB5EB-2307-425E-A06B-0D8C360B1994Q34345074-0D9C903D-C839-48EA-94EF-C90EE46F78AFQ34390574-640EFAFB-D252-4AEB-8630-653F41EB4CF0Q34650411-8877B706-3CD3-4441-86F6-0B9559B9D243Q34712671-C7C7CCA2-7960-47A1-940B-390FAC8CDE85Q34788079-C8639345-CED4-4CBF-AFF7-5721CED68811Q35001777-E4B2F7D5-2140-45C0-B853-6E713193124DQ35909807-2F5EF9E4-5093-4D01-87A1-6329D0D87480Q35923382-975BE61B-4DA1-46AB-847C-B012E8AFFE31Q36351873-6AFD3585-9062-4CD4-B038-24A0B314CDA1Q36632665-C4B559D3-7CDD-4B3B-873D-1B1EDA369035Q36664970-A212C47F-F768-4B7A-98AE-077A8BCBC7C6Q37474172-403EEB45-F8C5-4B7B-BE65-86681734E75BQ37647361-6696C14E-E922-443D-BA43-FBE84244B00FQ37957701-27197E0D-F824-45E6-BEF7-A484C3AA772AQ38150165-D6BFEDFC-DE9C-4F4E-98AB-076900A2DD89Q38860212-B2EC1B21-961A-4D0C-848B-B050D4151E5EQ38991944-67ABCD20-43A4-4740-BF36-516F8EB7C231Q41458940-22E971F0-08C9-467C-A90F-6AFC1CC25C19Q42090894-9AA5EC65-8E15-49B1-96F9-236CFF7900DDQ42371575-3E1BDFA9-8E88-4DAB-B31A-E4A577D81275Q43166070-9BAC7139-6920-4A1E-92B4-6872E32B51FEQ47197069-857F51ED-BE8A-41FC-A12C-76C80AFF55B1Q47999234-AC07DC99-9276-4D45-A35A-3979DAA1516AQ48526596-04DE740A-3D66-4EEE-8B30-6D690F5D194BQ50511434-D34ED464-412D-4394-8A4C-2F4153D0CEA8Q58003581-57FD2885-CD71-4A6C-B794-F8916751095B
P2860
Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Consequences of long-term prot ...... of patients with gastrinomas.
@ast
Consequences of long-term prot ...... of patients with gastrinomas.
@en
type
label
Consequences of long-term prot ...... of patients with gastrinomas.
@ast
Consequences of long-term prot ...... of patients with gastrinomas.
@en
prefLabel
Consequences of long-term prot ...... of patients with gastrinomas.
@ast
Consequences of long-term prot ...... of patients with gastrinomas.
@en
P2860
P1476
Consequences of long-term prot ...... of patients with gastrinomas.
@en
P2093
Robert T Jensen
P2860
P356
10.1111/J.1742-7843.2006.PTO_378.X
P577
2006-01-01T00:00:00Z